Kinarus Therapeutics (SIX: KNRS)

Currency in CHF

Last close As at 25/01/2023


0.00 (13.33%)

Market capitalisation


Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.

Upon availability of new funding, Kinarus plans to start a Phase II study in wet AMD, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.



Equity Analyst

Pooya Hemami

Pooya Hemami


Key Management

  • Dr. Alexander Bausch


  • Subhasis Roy


Balance Sheet

Forecast net debt (CHFm)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 44.1 70.0 (77.6)
Relative 36.5 55.3 (75.8)
52 week high/low CHF0.1/CHF0.0


Kinarus Therapeutics is advancing KIN001, a patented orally dosed combination of p38 mitogen-activated protein kinase inhibitor pamapimod and pioglitazone. Preclinical data suggest this combination may have anti-inflammatory and anti-fibrotic activity, as well as antiviral properties against COVID-19. KIN001 is under development for the treatment of wet age-related macular degeneration (wet AMD), its lead indication, as well as idiopathic pulmonary fibrosis and COVID-19. Wet AMD is a leading cause of vision loss in older adults and there are no oral drugs approved to treat the condition, signalling a potentially significant unmet need.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (fd) (CHFc) P/E (x) P/CF (x)
2020A 0.0 (1.5) (1.5) (31.17) N/A N/A
2021A 0.0 (5.1) (4.9) (0.41) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free